BEHANDLUNG VON KREBS

European patent · EP4096717 · In force

Register entry

Publication number
EP4096717
Application number
EP21702624
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jan 28, 2021
Published
Dec 7, 2022
Granted
Dec 11, 2024
Protection ends at the latest
Jan 27, 2041
Next annual fee due
Jan 31, 2027
IPC classes
A61K 47/68 (2017.01)
A61P 35/00 (2006.01)
Priority
US 202062968175 P 31.01.2020
PCT application
PCT/EP2021/051938 28.01.2021
PCT publication
WO2021/151984 05.08.2021
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 1, 2026

    Change

    Published in Swissreg on 01.02.2026

  2. Sep 24, 2025

    Change

    Published in Swissreg on 24.09.2025

  3. Sep 17, 2025

    Change

    Published in Swissreg on 17.09.2025

  4. Mar 6, 2025

    Change

    Published in Swissreg on 06.03.2025

  5. Dec 11, 2024

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 11.12.2024

Parties

Holder

Innate Pharma

117, Avenue de Luminy, 13009 Marseille, FR

Inventor

KRAIEM, Manel

13011 MARSEILLE, FR

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.